BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Manrique-Caballero CL, Kellum JA, Gómez H, De Franco F, Giacchè N, Pellicciari R. Innovations and Emerging Therapies to Combat Renal Cell Damage: NAD+ As a Drug Target. Antioxid Redox Signal 2021;:1-18. [PMID: 33499758 DOI: 10.1089/ars.2020.8066] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Cianci M, Giacchè N, Cialabrini L, Carotti A, Liscio P, Rosatelli E, De Franco F, Gasparrini M, Robertson J, Amici A, Raffaelli N, Pellicciari R. Structural Basis of Human Dimeric α-Amino-β-Carboxymuconate-ε-Semialdehyde Decarboxylase Inhibition With TES-1025. Front Mol Biosci 2022;9:834700. [DOI: 10.3389/fmolb.2022.834700] [Reference Citation Analysis]
2 Bai T, Cui Y, Yang X, Cui X, Yan C, Tang Y, Cao X, Dong C. miR-302a-3p targets FMR1 to regulate pyroptosis of renal tubular epithelial cells induced by hypoxia-reoxygenation injury. Exp Physiol 2021. [PMID: 34605097 DOI: 10.1113/EP089887] [Reference Citation Analysis]
3 Toro J, Manrique-Caballero CL, Gómez H. Metabolic Reprogramming and Host Tolerance: A Novel Concept to Understand Sepsis-Associated AKI. J Clin Med 2021;10:4184. [PMID: 34575294 DOI: 10.3390/jcm10184184] [Reference Citation Analysis]